Manysmart offers unique therapies based on cell-associated products.
We are devoted to providing more opportunities for people to fight against diseases and cancer.
Manysmart therapeutics has a core team that is dedicated to discover and design novel therapies.
We have developed a bispecific drug candidate for antibody combination therapy and a distinct treatment for cancer relapse prevention with our technology of Vγ9Vδ2 T cells.
γδ T cell is potential to fight cancer.
γδ T cell is one of the minorities of our T cell composition, activated by MHC-independent way. Vγ9Vδ2 T cell is the biggest subpopulation of γδ T cell, and it is part of the first-line immunity against cancer.
The research rising quickly until recent years because it is difficult to expand the Vγ9Vδ2 T cell.
It's believed that γδ T-cell is a potential candidate in cancer immunotherapy due to its anti-tumor property and allograft potential.